CAR

Increase Access to Life Saving Cancer Treatment with Accarent Health’s Oncology and Gene Therapy Bundles

Retrieved on: 
Tuesday, October 24, 2023
American Cancer Society, Survival, FDA, CAR, Food, Bone marrow, Najib Roger Accar, Certification, Death, Institute for Clinical and Economic Review, Disease, Transport, Partnership, Cancer, Hospital, Patient, Diagnosis, Food and Drug Administration Safety and Innovation Act, Pharmaceutical industry, MD

CAR T-Cell therapy is a specific kind of gene therapy being used to treat cancer.

Key Points: 
  • CAR T-Cell therapy is a specific kind of gene therapy being used to treat cancer.
  • Currently, six CAR T-cell therapies have been approved by the Food and Drug Administration (FDA) for the treatment of blood cancers.
  • Accarent Health, a unified technology and care management platform granting access to pre-negotiated, fixed bundled prices for complex medical procedures and treatments, offers a variety of cancer treatment bundles eliminating unpredictable costs and providing increased access to quality care.
  • For more information or to access these or other behavioral health treatment options visit Accarent Health at www.accarenthealth.com.

Accarent Health Offers Industry Leading Pediatric Network of Excellence

Retrieved on: 
Monday, October 23, 2023
We, CAR, Children's Hospital Los Angeles, Adolescence, Health, Patient, Fever, News, Congenital heart defect, Hospital, Craniotomy, U.S. News & World Report, Cancer, U.S. News & World Report Best Hospitals Rankings, Patient safety, Honors student, Nursing, MD

Pediatric specialists are often a better choice when treating severe or rare afflictions that could be severely detrimental or even fatal, to young children.

Key Points: 
  • Pediatric specialists are often a better choice when treating severe or rare afflictions that could be severely detrimental or even fatal, to young children.
  • In 2023, only 89 children’s hospitals were ranked in at least one of the 10 pediatric specialties evaluated.
  • As the premier pediatric network, Accarent Health is able to provide access to the best children’s hospitals nationwide, often to members who may not have had access otherwise.
  • Every hospital in the growing Accarent pediatric network was included in the U.S. News & World Report Best Children’s Hospitals Rankings.

Regen BioPharma, Inc. Receives Second Phase Confirmatory Data on its Duracar CAR-T Cell Therapy Program

Retrieved on: 
Wednesday, October 25, 2023
CAR, Central Waqf Council, Patent, Autoimmunity, CD19, OTC, Sirna Therapeutics, Quicc!, NR2F6, SAN, Vaccine

SAN DIEGO, Oct. 25, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) has previously discussed initiation of a series of experiments to validate its DuraCAR CAR T-cell therapeutic (https://www.prnewswire.com/news-releases/regen-biopharma-inc--begins-exp...) while also identifying new, unexpected and potentially extremely useful findings in developing cell therapy treatments for autoimmune disorders https://www.prnewswire.com/news-releases/studies-on-regen-biopharma-incs....

Key Points: 
  • The Company has now received the complete set of confirmatory data performed by a second contract research organization (CRO) which is independent of the CRO which performed the initial experiments.
  • These data confirm that T cells which express the chimeric antigen receptor (CAR) construct targeting CD19 and expressing siRNA for NR2F6 had high expression levels of NR2F6 mRNA.
  • NR2F6 is considered an immune checkpoint and thus increasing its activity is likely to lead to immune suppression.
  • "Having a second confirmatory study gives us confidence we are making the right decision to pursue these novel cell therapies focused on autoimmunity," says Dr. David Koos, Chairman and CEO of the company.

3T Biosciences Expands Leadership Team With Bryan Irving, Ph.D., as Chief Scientific Officer to Progress Tumor-specific Therapies to Clinic

Retrieved on: 
Wednesday, October 25, 2023
Knowledge, CAR, PD-L1, UCSF, CSO, IND, Autoimmunity, Therapy, Culture, TCR, Lightspeed Venture Partners, Investigational New Drug, University of California, CTA, Acquisition, Immunity, Research, Journal of Experimental Medicine, Harvard University, Inflammation, Multimedia, R, Journal, Cancer immunology, Cell, Nature Communications, Immune system, Amgen, Drug discovery, Cancer, Microbiology, Canadian Aviation Regulations, Medical research, Immunotherapy, University, Roche, Sanofi, Genentech, Safety, Patient, Doctor of Philosophy, Coronavirus Scientific Advisory Board, Management, Vaccine, Pharmaceutical industry, Science

SOUTH SAN FRANCISCO, Calif., Oct. 25, 2023 /PRNewswire/ -- 3T Biosciences ("3T"), an immunotherapy company changing the future of treatment for solid tumors and other immune-mediated diseases, today announced the appointment of Bryan Irving, Ph.D., as chief scientific officer (CSO). In this role, Dr. Irving will be responsible for the company's scientific strategy and direction and will chair 3T's Scientific Advisory Board.

Key Points: 
  • In this role, Dr. Irving will be responsible for the company's scientific strategy and direction and will chair 3T's Scientific Advisory Board.
  • His work has focused primarily on exploring ways to modulate T-cell activity for therapeutic benefit in both oncology and autoimmune settings.
  • "3T shares my passion for innovation and has a culture of rigor and dedication to advancing novel therapies.
  • 3T Biosciences is an immunotherapy company focused on discovering and developing next-generation therapies with curative potential based on its immune-response-guided target discovery approach.

Dove and Nike Team Up to Launch BODY CONFIDENT SPORT, a First-of-its-Kind Online Coaching Program to Help Build Body Confidence in Girls Globally

Retrieved on: 
Tuesday, October 24, 2023
Venus, Woman, Research, Sport, CAR, Pressure, Face, Gold, Gold medal, Nike, Athlete, Environment, VENUS, Partnership, School, Love, Body, Hearing, Toy, Tutoring, Columbidae

ENGLEWOOD CLIFFS, N.J., Oct. 24, 2023 /PRNewswire/ -- Girls who participate in physical activity – and stay with it through adolescence – are more likely to have higher body confidence and experience benefits throughout their lives. However, NEW research from Dove and Nike reveals 45% of teenage girls globally drop out of sports - at twice the rate of boys - with low body confidence as the biggest driver.

Key Points: 
  • However, NEW research from Dove and Nike reveals 45% of teenage girls globally drop out of sports - at twice the rate of boys - with low body confidence as the biggest driver.
  • For the first time ever, Dove – the world's largest provider of self-esteem and body confidence education – has teamed up with Nike – the biggest champion of athletes and sports – to launch the Body Confident Sport online coaching program.
  • Body Confident Sport is a first-of-its-kind, scientifically-proven set of coaching tools to build body confidence in 11–17-year-old girls.
  • According to the new findings from Dove and Nike, the sports environment impacts girls' body confidence and self-esteem:
    51% of girls dropping out were told that they are not good enough.

Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

Retrieved on: 
Tuesday, October 24, 2023
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Spectrum, CAR, ZFS, Congress, Inflammation, ZF, DSM-IV codes, Novartis, Cell, Gene, Partnership, SCN2A, Neurology, ESGCT, Multiple sclerosis, Intellectual disability, European Society of Gene and Cell Therapy, Therapy, Patient, Pharmaceutical industry, Medical imaging, Sangamo Therapeutics

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the European Society of Gene & Cell Therapy (ESGCT) has accepted six Sangamo abstracts for presentation at the 30th Annual Congress being held October 24-27, 2023, in-person in Brussels, Belgium.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the European Society of Gene & Cell Therapy (ESGCT) has accepted six Sangamo abstracts for presentation at the 30th Annual Congress being held October 24-27, 2023, in-person in Brussels, Belgium.
  • Presentations will focus on the progression of Sangamo’s pre-clinical programs, including data from its neurology epigenetic regulation programs, and advancements in the CAR-Treg pipeline.
  • “The data we are presenting at ESGCT reflect the important advances being made across our neurology and CAR-Treg pipelines,” said Jason Fontenot, Ph.D., Chief Scientific Officer at Sangamo.
  • This presentation will show how ZF-As can be designed to restore normal gene and protein expression of SCN2A in vitro and in vivo.

Alaya.bio Acquires Key Assets From Ixaka France, Accelerating the Progress of Its Novel In Vivo CAR-T Immunotherapy Platform

Retrieved on: 
Friday, October 20, 2023
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Health, Genetics, Other Health, CAR, Growth, CSO, Patent, General partnership, Acquisition, Vaccine

Alaya.bio , an in vivo gene delivery biotech company, announces today the acquisition of all assets previously owned by Ixaka France, a preclinical-stage immunotherapy biotech company specializing in in vivo CAR T-cell therapy.

Key Points: 
  • Alaya.bio , an in vivo gene delivery biotech company, announces today the acquisition of all assets previously owned by Ixaka France, a preclinical-stage immunotherapy biotech company specializing in in vivo CAR T-cell therapy.
  • Alaya.bio intends to leverage its combined assets to significantly simplify the way CAR-T cell therapies are being developed, manufactured and administered.
  • This acquisition accelerates Alaya.bio's programs significantly, providing data showing preclinical proof of concept of the anti-tumoral efficacy of in vivo engineered CAR T cells in immunocompetent mouse models.
  • It includes a broad and robust patent portfolio, preclinical data, and exclusive licenses for polymeric nanoparticle technology.

Regen BioPharma, Inc. Expects Second Phase of Confirmatory Study Shortly

Retrieved on: 
Wednesday, October 18, 2023
Quicc!, CAR, Cancer, Sirna Therapeutics, Messenger, NR2F6, Real-time, SAN, Vaccine

SAN DIEGO, Oct. 18, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC-PINK: RGBP) (OTC-PINK: RGBPP) is currently developing a genetic approach to regulating NR2F6 levels in human T cells.

Key Points: 
  • SAN DIEGO, Oct. 18, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC-PINK: RGBP) (OTC-PINK: RGBPP) is currently developing a genetic approach to regulating NR2F6 levels in human T cells.
  • The Company has recently received unexpected and potentially extremely useful data from one of its contract research organizations (CRO) retained to perform experimental studies on the Company's DuraCAR CAR T-cell therapeutic.
  • These studies demonstrated that T cells which express the chimeric antigen receptor (CAR) construct expressing siRNA for NR2F6 can be successfully created.
  • "A second unrelated CRO is currently performing qRT-PCR tests to determine if NR2F6 mRNA is elevated or inhibited by our  CAR in T-Cells," says Dr. Harry Lander, Chief Scientific Consultant to the Company."

Autolus Therapeutics to host virtual event to discuss the company’s obe-cel program in systemic lupus erythematosus

Retrieved on: 
Tuesday, October 17, 2023
PIN, University College London, Conference call, Therapy, Webcast, ET, CAR, BST, Hospital, University College London Hospitals NHS Foundation Trust, Conference, SLE

LONDON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will hold a virtual event on Tuesday, October 24, 2023 at 8:30 am ET, 1:30 pm BST, to discuss the company’s CAR T strategy in autoimmune diseases and recent decision to advance obecabtagene autoleucel (obe-cel) into a Phase 1 study in systemic lupus erythematosus (SLE) in early 2024.

Key Points: 
  • LONDON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will hold a virtual event on Tuesday, October 24, 2023 at 8:30 am ET, 1:30 pm BST, to discuss the company’s CAR T strategy in autoimmune diseases and recent decision to advance obecabtagene autoleucel (obe-cel) into a Phase 1 study in systemic lupus erythematosus (SLE) in early 2024.
  • The event will include an introduction from Autolus’s Chief Executive Officer, Dr Christian Itin, and presentations from key thought leader, Dr Maria Leandro, consultant rheumatologist at UCL Hospitals and senior lecturer at University College London, and company management.
  • Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.
  • A simultaneous audio webcast and replay along with presentation materials will be accessible on the events section of Autolus’s website.

Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

Retrieved on: 
Tuesday, October 17, 2023
Investment, Food, Lupus nephritis, Division, Death, Cytarabine, NKG2D, Risk, Rituximab, IND, Safety, University, AML, Conference call, AID, Brattleboro Retreat, Autoimmune disease, Dialysis, FDA, B-cell lymphoma, Workforce, Department of Medicine – University of Pamplona, Lupus, ET, CAR, Immune system, Patient, End organ damage, Rheumatic Disease Clinics of North America, LN, Kidney disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, SAN, MRD, NK, University of Massachusetts Chan Medical School, Parikh, Conference, Investigational New Drug, SLE, NHL, Pharmaceutical industry, Vaccine, Cryptocurrency, Nursing, LD, Rheumatology, Medicine

(1)

Key Points: 
  • (1)
    The multi-center, open label, dose escalation clinical trial will assess the safety and clinical activity of NKX019 in patients with refractory LN.
  • “The clearance of Nkarta’s IND for NKX019 in lupus nephritis is an important achievement for Nkarta, and we feel NK cell therapy is ideally suited for the treatment of autoimmune disease,” said Paul J. Hastings, President and CEO of Nkarta.
  • Nkarta announced today the opening of a new cohort in its Phase 1 study of NKX019 in r/r NHL.
  • Nkarta management will discuss its program in autoimmune disease and other corporate updates on Tuesday, October 17, at 8:00 a.m.